Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo

Journal of Biochemical and Molecular Toxicology

Volumn 26, Issue 1, 2012, Pages 35-43

  Wang, Chunmei ^a   Lu, Jie ^b   Wang, Yumei ^b   Bai, Songting ^a   Wang, Yingchao ^a   Wang, Lu ^a   Sheng, Guangyao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Apoptosis; FLT3; Inhibitor; NF B; Tumor growth

Indexed keywords

ANTILEUKEMIC AGENT; CD135 ANTIGEN; CYCLIN D1; PARTHENOLIDE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; SC 203048; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CYCLIN D1; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; NUCLEAR RECEPTOR CO-REPRESSOR 2; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES; THIOPHENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856382461     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20411     Document Type: Article

References (32)

1. Haferlach T. Molecular genetic pathways as therapeutic targets in acute leukemia. Hematology Am Soc Hematol Educ Program 2008; 1: 400-411.
2. O'Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG, Millenson M, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stone RM, Tallman MS, Wang E, White FL. Acute myeloid leukemia. J Natl Compr Canc Netw 2008; 6: 962-993.
3. Smith ML, Hills RK, Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011; 25: 39-51.
4. Zhai XW, Cheng FW, Lee V, Leung WK, Ng MH, Tsang KS, Shing MK, Li CK. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children. Pediatr Hematol Oncol 2011; 28: 269-278.
5. Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program 2010; 2010: 47-55.
6. Scholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008; 35: 336-345.
7. Sino-U.S, Shanghai Leukemia Cooperative Group. FLT3 gene mutation and its prognostic implication in patients with acute leukemia. Zhonghua Xue Ye Xue Za Zhi 2010; 31: 1-5.
8. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 3622-36266.
9. Chan PM. Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model. Protein Cell 2011; 2: 108-115.
10. Leow S, Kham SK, Ariffin H, Quah TC, Yeoh AE. FLT3 mutation and expression did not adversely affect clinical outcome of childhood acute leukaemia-a study of 531 Southeast Asian children by the Ma-Spore study group. Hematol Oncol 2011; doi: 10.1002/hon.987.
11. Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 2005; 90: 1617-1625.
12. Kang HJ, Lee JW, Kho SH, Kim MJ, Seo YJ, Kim H, Shin HY, Ahn HS. High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia. J Korean Med Sci 2010; 25: 841-845.
13. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002; 100: 2393-2398.
14. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T. Analysis of FLT3 activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes kind identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
15. Lu Y, Kitaura J, Oki T, Komeno Y, Ozaki K, Kiyono M, Kumagai H, Nakajima H, Nosaka T, Aburatani H, Kitamura T. Identification of TSC-22 as a potential tumor suppressor that is upregulated by FIt3-D835V but not Flt3 ITD. Leukemia 2007; 21: 2246-2257.
16. Scho US, Krause C, Loncarevic IF. Specific detection of FLT3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. J Clin Med 2005; 145: 295-304.
17. Choudhary C, Brandts C, Schwable J. Activation mechanisms of STAT5 by oncogenic Flt3 ITD. Blood 2007; 110: 370-374.
18. Aggarwal BB. Nuclear factor-κB: the enemy within, Cancer Cell 2004; 6: 203-208.
19. Oka D, Nishimura K, Shiba M, Nakai Y, Arai Y, Nakayama M, Takayama H, Inoue H, Okuyama A, Nonomura N. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-κB. Int J Cancer 2007; 120: 2576-2525.
20. Taguchi T, Takao T, Iwasaki Y, Nishiyama M, Asaba K, Hashimoto K. Suppressive effects of dehydroepiand- rosterone and the nuclear factor-κB inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo. J Endocrinol 2006; 188: 321-331.
21. -ΔΔCt method. Methods 2001; 25: 402-408.
22. Kitamura T, Itoh M, Noda T, Matsuura M, Wakabayashi K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer 2004; 109: 576-580.
23. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Mutant FLT3: a direct target of sorafenib in acute myeloid leukemia. J Natl Cancer Inst 2008; 100: 184-198.
24. Lounnas N, Frelin C, Gonthier N, Colosetti P, Sirvent A, Cassuto JP, Berthier F, Sirvent N, Rousselot P, Dreano M, Peyron JF, Imbert V. NF-κB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T3151 Bcr-Abl mutants. Int J Cancer 2009; 125: 308-317.
25. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110: 4427-4435.
26. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-κB function in growth control: regulation of cyclinD1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999; 19: 2690-2698.
27. Ghoshal P, Nganga AJ, Moran-Giuati J, Szafranek A, Johnson TR, Bigelow AJ, Houde CM, Avet-Loiseau H, Smiraglia DJ, Ersing N, Chanan-Khan AA, Coignet LJ. Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res 2009; 69: 4380-4387.
28. Green AR, Burney C, Granger CJ, Paish EC, El-Sheikh S, Rakha EA, Powe DG, Macmillan RD, Ellis IO, Stylianou E. The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 2008; 110: 427-437.
29. Battaglia S, Maguire O, Campbell MJ. Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer 2010; 126: 2511-2519.
30. Wang C, Sheng G, Lu Jie, Zou X, Fang Y, Bai S, Xie L. Interactions of p65 and SMRT by co-immunoprecipitation. J Shandong Univ (Med Sci) 2010; 48: 51-55.
31. Rong Y, Distelhorst CW. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol 2008; 70: 73-91.
32. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE. NFκB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 2001; 276: 45380-45386.